Alerts
PDF
Other content recommended for you
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization
- PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages
- Blockade of AIM2 inflammasome or α1-AR ameliorates IL-1β release and macrophage-mediated immunosuppression induced by CAR-T treatment
- Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
- The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
- Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
- Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma